인크레틴 기반 약물 시장 보고서(2026년)

Incretin-based drugs are medications used to manage type 2 diabetes by enhancing the action of incretin hormones, which stimulate insulin release after meals. These drugs help regulate blood sugar levels, reduce appetite, and support weight loss. They also lower the risk of sharp blood sugar spikes and generally do not cause severe hypoglycemia.

The main types of incretin-based drugs include glucagon-like peptide-1 receptor (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. GLP-1 receptor agonists imitate natural GLP-1 to boost insulin, suppress glucagon, slow gastric emptying, and lower blood sugar in type 2 diabetes and obesity. They are administered via oral or injectable routes and distributed through hospital pharmacies, retail pharmacies, and online pharmacies for applications such as type 2 diabetes, obesity, and related conditions.

Tariffs have influenced the incretin-based drugs market by increasing costs for active pharmaceutical ingredients, injectable delivery devices, and formulation excipients used in GLP-1 agonists and DPP-4 inhibitors. Injectable diabetes and obesity therapies are most affected, particularly in North America and Europe, where a significant portion of APIs and pen-delivery systems are sourced internationally. Hospital and retail pharmacies are experiencing higher acquisition costs that impact patient access. On the positive side, tariffs are accelerating domestic API manufacturing and local fill-and-finish operations for incretin-based drugs.

The incretin-based drugs market research report is one of a series of new reports from The Business Research Company that provides incretin-based drugs market statistics, including incretin-based drugs industry global market size, regional shares, competitors with a incretin-based drugs market share, detailed incretin-based drugs market segments, market trends and opportunities, and any further data you may need to thrive in the incretin-based drugs industry. This incretin-based drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The incretin-based drugs market size has grown strongly in recent years. It will grow from $27.83 billion in 2025 to $29.88 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to type 2 diabetes prevalence, insulin resistance rates, lifestyle-related metabolic disorders, endocrinology drug adoption, hospital diabetes programs.

The incretin-based drugs market size is expected to see strong growth in the next few years. It will grow to $39.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to global obesity epidemic, weight management drug demand, long-acting incretin innovation, personalized diabetes care, preventive metabolic health focus. Major trends in the forecast period include rapid adoption of glp-1 receptor agonists, expansion of obesity management indications, increased use of oral incretin therapies, growing combination therapy approaches, improved patient adherence through weekly dosing.

The increasing prevalence of type 2 diabetes mellitus is expected to drive growth in the incretin-based drugs market in the coming years. Type 2 diabetes mellitus is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to elevated blood glucose levels. Its rising prevalence is primarily due to poor diet and physical inactivity, which contribute to insulin resistance and reduce the body's ability to regulate blood sugar. Incretin-based drugs improve type 2 diabetes management by enhancing insulin release after meals and reducing glucagon production, thereby lowering blood sugar levels. They also slow gastric emptying and suppress appetite, supporting glucose control and weight management. For example, according to the National Health Service in June 2024, approximately 549,000 more people in England were at risk of developing type 2 diabetes in 2023, bringing the total number with pre-diabetes to over 3.6 million-a nearly 20% increase from 2022. Consequently, the rising prevalence of type 2 diabetes mellitus is fueling growth in the incretin-based drugs market.

Key companies in the incretin-based drugs market are focusing on developing generic versions to provide more effective and patient-friendly treatment options for type 2 diabetes. Generic drugs contain the same active ingredients, strength, dosage form, and route of administration as brand-name drugs but are marketed under their chemical name without brand labeling. For instance, in December 2024, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, launched the first generic version of Victoza (liraglutide) injection, 6 mg/mL, in the United States, following FDA approval. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, providing a more affordable option amid ongoing shortages of GLP-1 medications.

In July 2024, Roche, a Switzerland-based pharmaceutical company, acquired Carmot Therapeutics for approximately $2.7 billion. This acquisition strengthens Roche's position in the rapidly expanding obesity and metabolic disease market by integrating Carmot's innovative injectable and oral therapies into its pharmaceuticals division. Carmot Therapeutics is a US-based clinical-stage biotechnology company specializing in obesity and diabetes, with a focus on incretin-based therapies, including GLP-1 and GIP receptor agonists.

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

North America was the largest region in the incretin-based drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the incretin-based drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The incretin-based drugs market consists of sales of dual or multi-agonists, glucagon receptor co-agonists, and fixed-dose combination drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the drugs, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the drugs.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Incretin-Based Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses incretin-based drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for incretin-based drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The incretin-based drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists; Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
• 2) By Route Of Administration: Oral; Injectable
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Type 2 Diabetes; Obesity; Other Applications
• Subsegments:
• 1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide; Liraglutide; Dulaglutide; Semaglutide; Lixisenatide
• 2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin; Vildagliptin
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; AbbVie Inc.; Bristol-Myers Squibb Company; AstraZeneca PLC; Novartis AG; GlaxoSmithKline plc; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Amgen Inc.; Novo Nordisk A/S; Viatris; Boehringer Ingelheim GmbH; Astellas Pharma Inc.; Daiichi Sankyo Company Limited; Sun Pharmaceutical Industries Ltd.; Sumitomo Dainippon Pharma Co. Ltd.; Hikma Pharmaceuticals PLC; Lupin Limited; Mitsubishi Tanabe Pharma Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Incretin-Based Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Incretin-Based Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Incretin-Based Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Incretin-Based Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rapid Adoption Of Glp-1 Receptor Agonists
  • 4.2.2 Expansion Of Obesity Management Indications
  • 4.2.3 Increased Use Of Oral Incretin Therapies
  • 4.2.4 Growing Combination Therapy Approaches
  • 4.2.5 Improved Patient Adherence Through Weekly Dosing

5. Incretin-Based Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Diabetes Care Centers
• 5.3 Specialty Clinics
• 5.4 Endocrinology Clinics
• 5.5 Homecare Settings

6. Incretin-Based Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Incretin-Based Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Incretin-Based Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Incretin-Based Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Incretin-Based Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Incretin-Based Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Incretin-Based Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Incretin-Based Drugs Market Segmentation

• 9.1. Global Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
• 9.2. Global Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable
• 9.3. Global Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.4. Global Incretin-Based Drugs Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Type 2 Diabetes, Obesity, Other Applications
• 9.5. Global Incretin-Based Drugs Market, Sub-Segmentation Of Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide
• 9.6. Global Incretin-Based Drugs Market, Sub-Segmentation Of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

10. Incretin-Based Drugs Market Regional And Country Analysis

• 10.1. Global Incretin-Based Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Incretin-Based Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Incretin-Based Drugs Market

• 11.1. Asia-Pacific Incretin-Based Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Incretin-Based Drugs Market

• 12.1. China Incretin-Based Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Incretin-Based Drugs Market

• 13.1. India Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Incretin-Based Drugs Market

• 14.1. Japan Incretin-Based Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Incretin-Based Drugs Market

• 15.1. Australia Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Incretin-Based Drugs Market

• 16.1. Indonesia Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Incretin-Based Drugs Market

• 17.1. South Korea Incretin-Based Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Incretin-Based Drugs Market

• 18.1. Taiwan Incretin-Based Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Incretin-Based Drugs Market

• 19.1. South East Asia Incretin-Based Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Incretin-Based Drugs Market

• 20.1. Western Europe Incretin-Based Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Incretin-Based Drugs Market

• 21.1. UK Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Incretin-Based Drugs Market

• 22.1. Germany Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Incretin-Based Drugs Market

• 23.1. France Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Incretin-Based Drugs Market

• 24.1. Italy Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Incretin-Based Drugs Market

• 25.1. Spain Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Incretin-Based Drugs Market

• 26.1. Eastern Europe Incretin-Based Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Incretin-Based Drugs Market

• 27.1. Russia Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Incretin-Based Drugs Market

• 28.1. North America Incretin-Based Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Incretin-Based Drugs Market

• 29.1. USA Incretin-Based Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Incretin-Based Drugs Market

• 30.1. Canada Incretin-Based Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Incretin-Based Drugs Market

• 31.1. South America Incretin-Based Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Incretin-Based Drugs Market

• 32.1. Brazil Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Incretin-Based Drugs Market

• 33.1. Middle East Incretin-Based Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Incretin-Based Drugs Market

• 34.1. Africa Incretin-Based Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Incretin-Based Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Incretin-Based Drugs Market Regulatory and Investment Landscape

36. Incretin-Based Drugs Market Competitive Landscape And Company Profiles

• 36.1. Incretin-Based Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Incretin-Based Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Incretin-Based Drugs Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

37. Incretin-Based Drugs Market Other Major And Innovative Companies

• AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited

38. Global Incretin-Based Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Incretin-Based Drugs Market

40. Incretin-Based Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Incretin-Based Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Incretin-Based Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Incretin-Based Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer